Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy / 医学前沿
Frontiers of Medicine
;
(4): 307-321, 2022.
Artigo
em Inglês
| WPRIM
| ID: wpr-939881
ABSTRACT
The discovery of immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has played an important role in the development of cancer immunotherapy. However, immune-related adverse events often occur because of the enhanced immune response enabled by these agents. Antibiotics are widely applied in clinical treatment, and they are inevitably used in combination with immune checkpoint inhibitors. Clinical practice has revealed that antibiotics can weaken the therapeutic response to immune checkpoint inhibitors. Studies have shown that the gut microbiota is essential for the interaction between immune checkpoint inhibitors and antibiotics, although the exact mechanisms remain unclear. This review focuses on the interactions between immune checkpoint inhibitors and antibiotics, with an in-depth discussion about the mechanisms and therapeutic potential of modulating gut microbiota, as well as other new combination strategies.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Receptor de Morte Celular Programada 1
/
Inibidores de Checkpoint Imunológico
/
Imunoterapia
/
Antibacterianos
/
Neoplasias
Tipo de estudo:
Pesquisa qualitativa
Limite:
Humanos
Idioma:
Inglês
Revista:
Frontiers of Medicine
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS